KRAS as a predictor of poor prognosis and benefit from postoperative FOLFOX chemotherapy in patients with stage II and III colorectal cancerYanhong Deng, Jianping Wang, Li Wang et al.|Molecular Oncology|2015Cited by 60
Celecoxib Downregulates CD133 Expression Through Inhibition of the Wnt Signaling Pathway in Colon Cancer CellsYanhong Deng, Edward H. Lin, Qiao Su et al.|Cancer Investigation|2012Cited by 43
Demographic trends and <i>KRAS/BRAF</i><sup><i>V600E</i></sup> mutations in colorectal cancer patients of South China: A single‐site reportXinhui Fu, Ping Lan, Jian‐ping Wang et al.|International Journal of Cancer|2018Cited by 28
Prognostic value of different B symptoms in upper aerodigestive tract NK/T-cell lymphomaJiadong Xiao, S. Ye, Xiao‐Yong Pu et al.|Journal of Clinical Oncology|2009Cited by 0